Clinical Trials Logo

Clinical Trial Summary

The present protocol aims to test, whether an approach using (i) a reduced-toxicity TBF followed by a (ii) Daratumumab maintenance and (iii) prophylactic infusion of donor lymphocytes (pDLI), will be able to improve progression-free survival of patients with refractory or relapsed MM. This trial represents the first prospective protocol aiming to test the use of Daratumumab maintenance after HLA-identical or haploidentical allo-SCT in patients with MM.


Clinical Trial Description

Allogeneic stem cell transplantation in patients with multiple myeloma (MM) Outcomes for patients with MM who are resistant to proteasome inhibitors (bortezomib) and immunomodulatory drugs (lenalidomide, thalidomide) are dramatically poor. The median expected overall survival (OS) in these patients is 9 months. New drugs such as pomalidomide or carfilzomib, when used in monotherapy, can only offer a median progression free survival (PFS) of 3.8 months and OS of 11.9 and 13.4 months, respectively.

Allogeneic stem cell transplantation (allo-SCT) remains the most reasonable treatment option, apart from palliative care, in patients with refractory or relapsed MM. No other strategy is able to offer any chance of cure for a patient at this stage. However, in the context of standard myeloablative (MAC) allo-SCT, results are limited in terms of feasibility in the larger patients' population who is in need, and by both a relatively high relapse incidence (RI) and especially high non-relapse mortality (NRM). Also, in the last decade, the advent of reduced intensity conditioning (RIC) allo-SCT and the improvement in supportive care management regarding infectious complications allowed a significant reduction of NRM. RIC expanded the transplant option to those patients who are ineligible for standard MAC allo-SCT either because of age or because of pre-existing comorbid conditions. While NRM is over 40% with MAC, relapse incidence remains high with either RIC or MAC. The major reason for treatment failure after allo-SCT for MM has become relapse, which is between 38% and 55%. Median PFS ranges from 10% to 32%. Thus, strategies to prevent relapse after allo-SCT for MM remain an unmet medical need.

Post-transplant maintenance therapy Consolidation/maintenance post-transplantation for MM has demonstrated to not only upgrade but also deepen the response, which translates into improved PFS. Studies investigated immunomodulatory drugs, thalidomide or lenalidomide, as maintenance therapy after allo-SCT. The observed activation of natural killer and regulatory T cells induced by immunomodulatory drugs provides an attractive rationale for its use post-transplant. But some concerns are raised by a high rate of graft-versus-host disease (GVHD) induction. In the prospective HOVON 76 trial, 43% patients stopped lenalidomide maintenance because of development of GVHD, 17% patients because of other adverse events, and 17% patients because of progression. Thus, lenalidomide maintenance after RIC allo-SCT in MM patients is not feasible, mainly because of the toxicity and the induction of acute GVHD.

Daratumumab, a human IgG1 monoclonal antibody that binds CD38-expressing malignant cells with high affinity and induces tumor cell death, has recently shown promising results in a phase 2 trial. Daratumumab was well tolerated, median PFS was 3.7 months and median duration of response was 7.4 months in patients who were refractory to both proteasome inhibitors and immunomodulatory drugs. Our first pilot experience, based on 3 patients with refractory MM suggests that Daratumumab maintenance is feasible. No grade 3-4 toxicities were observed. None of the patients experienced GVHD. After a median follow-up of 12 months, none of these patients relapsed. Thus, Daratumumab appears to be the ideal candidate to propose immunotherapy maintenance and reinforce the post-transplant immunomodulation strategy.

Prophylactic donor lymphocyte infusions Given that relapsed or refractory patients are at very high risk of relapse, prophylactic donor lymphocyte infusion (pDLI) is a promising approach to prevent relapse after allo-SCT. pDLI can improve remission status in 54% of the patients and result in 5-year PFS of 79%. The incidence and severity of acute GVHD remains manageable.

Type of donor Haploidentical family donors allow finding a quickly available donor for a majority of patients. T-cell replete haploidentical allo-SCT has now become feasible with the use of post-graft Cyclophosphamide, which reduces the risk of GVHD. In patients with relapsed or refractory hematologic malignancies, studies show no significant difference in terms of toxicity and outcomes between patients undergoing allo-SCT from a HLA-identical sibling and a haploidentical donor. Compared with unrelated donors, the outcomes are improved in haploidentical recipients. Thus, for these advanced patients, one should look first for a related donor, either matched or haploidentical. Searching for an unrelated donor may delay the procedure, with a risk of losing the opportunity for transplantation, and may be associated with worse outcomes compared with haploidentical allo-SCT.

Few studies have reported the outcomes of patients with MM after haploidentical allo-SCT. The most encouraging results have been reported with the RIC associating thiotepa, busulfan and fludarabine (TBF) in patients with heavily pretreated MM. The median 18-month PFS, OS and NRM were 33%, 63% and 10%, respectively.

The present protocol aims to test, whether an approach using (i) a reduced-toxicity TBF followed by a (ii) Daratumumab maintenance and (iii) prophylactic infusion of donor lymphocytes (pDLI), will be able to improve progression-free survival of patients with refractory or relapsed MM. This trial represents the first prospective protocol aiming to test the use of Daratumumab maintenance after HLA-identical or haploidentical allo-SCT in patients with MM.

This is a prospective, multicenter, open, non-randomized Phase II study that will include a total number of 38 patients included over a period of 2 years.

The population of the study is women and men adults (18-70 years) with refractory or relapsed multiple myeloma.

Treatment period will be 12 months Duration of inclusions will be 24 months So, total study duration (eg. 12 months after inclusion of last patient)will be 36 months

Each patient will receive: Daratumumab, 16 mg/kg, once a week for 8 weeks (cycles 1 and 2); then every 2 weeks for 16 weeks (cycles 3-6), then every 4 weeks thereafter (cycles 7-12).

A Patient is only eligible if:

- Absolute neutrophil count > 1 G/L

- Haemoglobin concentration > 7.5 g/dL

- Platelets > 50 G/L

- Estimated glomerular filtration rate > 20 mL/min according to CDK-EPI

- Is free of grade 2-4 acute GVHD since >30 days

- Is free of active infections

Is an interim analysis planned, if yes, list and specify timing(s): no Final study report timing after Last Patient, Last Visit: 3 months Publication submission timing after final study report: 3 months

The primary objective is to demonstrate that PFS at 12 months is higher than 40%. The trial would be designed to test the hypothesis P < 20% versus P>40% with one sided type I error rate 5% and power 80%. Using a one step A'Hern procedure, 35 patients should be transplanted. The analysis will be based on a binomial test comparing the observed 12 months PFS to 40%. In all, 38 patients will be included (taking into account that after registration, there is a risk of dropout i.e. patients, who will not receive a transplant due to rapidly progressive disease, infection or other events occurring after identification of a donor, but before start of conditioning). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04024384
Study type Interventional
Source Assistance Publique - Hôpitaux de Paris
Contact
Status Withdrawn
Phase Phase 2
Start date July 2019
Completion date July 2024

See also
  Status Clinical Trial Phase
Recruiting NCT05027594 - Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02412878 - Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma Phase 3
Completed NCT01947140 - Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies Phase 1/Phase 2
Recruiting NCT05971056 - Providing Cancer Care Closer to Home for Patients With Multiple Myeloma N/A
Recruiting NCT05243797 - Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation Phase 3
Active, not recruiting NCT04555551 - MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma Phase 1
Recruiting NCT05618041 - The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies N/A
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Completed NCT02916979 - Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG Phase 1
Recruiting NCT03570983 - A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion Phase 2
Terminated NCT03399448 - NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) Phase 1
Completed NCT03665155 - First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody Phase 1/Phase 2
Completed NCT02812706 - Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients Phase 1/Phase 2
Active, not recruiting NCT05024045 - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers Phase 1
Active, not recruiting NCT03989414 - A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) Phase 1/Phase 2
Active, not recruiting NCT03792763 - Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients Phase 2
Withdrawn NCT03608501 - A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation Phase 2
Recruiting NCT04537442 - Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02546167 - CART-BCMA Cells for Multiple Myeloma Phase 1